SAN FRANCISCO & SEOUL, Korea--()--AmStem Corporation (OTCBB:AMSTE), a leading provider of biotherapeutic and cosmetic stem cell products, stem cell collection and storage expertise and access to nanotechnology vital to stem cell research, announced today the formation of its Scientific and Medical Board of Advisors with the leadership appointments of co-chairmen Dr. Philip A. Lowry from Pennsylvania and Dr. Han Hoon, founder and director of the company’s laboratory facility in Seoul, Korea.
“I have had the privilege of working with Dr. Lowry on stem cell projects in the past, and I consider his participation on AmStem’s SAMBA further validation of Dr. Hans’ work at AmStem”
Announcing the creation of the Scientific and Medical Board of Advisors (SAMBA), AmStem President Dwight Brunoehler said, “The leadership and scientific credentials of Dr. Han and Dr. Lowry, together with additional new members of this Board that will be announced shortly, will be instrumental in building strong international relationships and expanding scientific and business opportunities related to stem cell transplantation and regenerative medicine.
“I have had the privilege of working with Dr. Lowry on stem cell projects in the past, and I consider his participation on AmStem’s SAMBA further validation of Dr. Hans’ work at AmStem,” Brunoehler said.
Dr. Lowry stated, “AmStem and Dr. Han have a vision to develop sound medical platforms for using stem cell research to improve the quality and longevity of human life. The SAMBA will immediately begin reviewing AmStem’s extensive stem cell patent portfolio in preparation to meet USFDA and international standards and pave the way for their use in the clinical setting. In addition, the team is anxious to explore new areas in this rapidly developing area of science.”
Dr. Han Hoon, president of Histostem Korea said, “We are very fortunate to attract the talent of Dr. Lowry. His balanced experience in academic and community settings bring unique strengths to his role as medical advisor for AmStem. With almost two decades of experience in stem cell transplantation and as a participant in early research into basic stem cell biology, Dr. Lowry brings a wealth of experience in both the fundamental and practical aspects of stem cell transplantation.”
Dr. Lowry received his undergraduate degree from Harvard College before going on to Yale University School of Medicine. He trained in internal medicine at the University of Virginia and received fellowship training in hematology and oncology there as well. He has twice served on the faculty at the University of Massachusetts Medical Center from 1992-1996 and from 2004-2009 as an assistant and then associate clinical professor of medicine establishing the bone marrow and stem cell transplantation program there, pursuing research in stem cell biology. He then served as medical director of the Cryopreservation Lab supporting the transplant program, as well as teaching and coordinating the second year medical school course in hematology and oncology. Dr. Lowry has ten years of experience in the community practice of hematology and oncology.
Dr. Lowry recently was named Chief of Hematology/Oncology for the Guthrie Health System, a three-hospital tertiary care system serving northern Pennsylvania and southern New York State.
About AmStem Inc.
AmStem Inc. is a corporation registered in the State of Nevada with offices in San Francisco, California and Seoul, Korea. The company is a world leader in the area of stem cell research using stem cells derived from the umbilical cord immediately after birth. The company has 19 U.S. and international patents related to stem cell processing, application and clinical treatments. AmStem owns one of the largest cord blood stem cell banks in the world with more than 80,000 cord blood units stored in Korea. The facility in Korea is highly accredited including Korean FDA approval (KFDA). The units of cord blood are processed and stored by the company for use in unrelated transplant for personal storage and use in the family setting for transplant and regenerative medicine. The company is developing a line of cosmeceuticals based upon its proprietary stem cell technology and sourcing its own materials from its expansive operation in Korea. The company has treated more than 800 people in clinical trials for purposes of developing its patent portfolio.
An investment profile on AmStem may be found at http://www.hawkassociates.com/profile/amst.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.
For more information contact AmStem President Dwight Brunoehler at (415) 956-2410 or Tom Fox at Hawk Associates at (305) 451-1888 or visit: http://amsteminc.com.
Forward-Looking Statements
Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for AmStem Corporation, may be forward-looking statements that involve a number of risks and uncertainties. For these statements, we claim the protection of the safe harbor for forward-looking statement contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, successfully complete clinical trials, our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capability or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in the press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statement to reflect events or circumstances that occur after the date hereof.
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
